×
AllNewsImages Maps Videos Books
Search tools

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX)

Seeking Alpha
Celldex Therapeutics, Inc.'s barzolvolimab has promise in urticaria treatment despite an eosinophilic esophagitis trial setback.
8 hours ago

Celldex Phase II barzolvolimab trial in EoE to be discontinued

The Pharma Letter
Biotechnology. 21 August 2025. More on this story... Celldex keeps climbing on barzolvolimab's effect in urticaria · Biotechnology.
13 hours ago

Celldex's Strategic Pivotal Shift: From EoE Setback to GI Innovation Opportunity with Barzolvolimab

AInvest
The biotech sector is no stranger to volatility, but. Celldex · CLDX. --. Therapeutics' recent recalibration of its pipeline offers a...
7 hours ago

LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT

Yahoo Finance
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12, Sam Slutsky from LifeSci...
1 day ago

Celldex drops EoE mAb despite meeting primary endpoint

Clinical Trials Arena
Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in other indications.
1 day ago

Celldex nixes development of barzolvolimab in eosinophilic esophagitis

FirstWord Pharma
Shares in Celldex Therapeutics fell 13% on Wednesday after the company said it...
1 day ago

Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial

Fierce Biotech
Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a phase 2 trial.
1 day ago

Lowering the mast: EoE theory down after Celldex phase II

BioWorld MedTech
Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a look at top-line...
1 day ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

GlobeNewswire
Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast...
2 days ago

Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics (NASDAQ:CLDX)

Benzinga
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom...
1 day ago